Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 0.72 |
| ▸ | KDR | P35968 | 20/20 | 0.72 |
| ▸ | AURKA | O14965 | 1/20 | 0.68 |
| ▸ | FPR1 | P21462 | 1/20 | 0.68 |
| ▸ | FPR3 | P25089 | 1/20 | 0.68 |
| ▸ | GPR183 | P32249 | 1/20 | 0.68 |
| ▸ | SMO | Q99835 | 1/20 | 0.68 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3570323 | 0.95 | MET (0.73) | METKDRAURKAFPR1FPR3 | |
| SCHEMBL3573926 | 0.91 | MET (0.67) | METKDRAURKAFPR1FPR3 | |
| SCHEMBL3566009 | 0.91 | MET (0.68) | METKDRAURKAFPR1FPR3 | |
| SCHEMBL3571364 | 0.90 | MET (0.75) | METKDRAURKAFPR1FPR3 | |
| SCHEMBL3559785 | 0.90 | MET (0.79) | METKDRAURKAFPR1FPR3 | |
| SCHEMBL13185373 | 0.89 | MET (0.74) | METKDRAURKAFPR1FPR3 | |
| SCHEMBL3567947 | 0.89 | MET (0.70) | METKDRAURKAFPR1FPR3 | |
| SCHEMBL2287810 | 0.89 | MET (0.90) | METKDRAURKAFPR1FPR3 | |
| SCHEMBL3564073 | 0.89 | MET (0.75) | METKDRAURKAFPR1FPR3 | |
| SCHEMBL3563553 | 0.89 | MET (0.69) | METKDRAURKAFPR1FPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1781664-B1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE INC (CA) | 2013-09-04 | — | — | EP | disclosed |
| US-8470850-B2 | Inhibitors of VEGF receptor and HGF receptor signalling | METHYLGENE INC. (CA) | 2013-06-25 | — | — | US | disclosed |
| US-8470850-B2 | Inhibitors of VEGF receptor and HGF receptor signalling | METHYLGENE INC. (CA) | 2013-06-25 | — | — | US | disclosed |
| US-8470850-B2 | Inhibitors of VEGF receptor and HGF receptor signalling | METHYLGENE INC. (CA) | 2013-06-25 | — | — | US | disclosed |
| US-20100249145-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signaling | METHYLGENE, INC. | 2010-09-30 | — | — | US | disclosed |
| US-20100249145-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signaling | METHYLGENE, INC. | 2010-09-30 | — | — | US | disclosed |
| US-20100249145-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signaling | METHYLGENE, INC. | 2010-09-30 | — | — | US | disclosed |
| US-7790729-B2 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2010-09-07 | — | — | US | disclosed |
| US-7790729-B2 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2010-09-07 | — | — | US | disclosed |
| US-7790729-B2 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2010-09-07 | — | — | US | disclosed |
| US-20100216766-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signalling | 92229129 QUEBEC INC. (CA) | 2010-08-26 | — | — | US | disclosed |
| US-20100216766-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signalling | 92229129 QUEBEC INC. (CA) | 2010-08-26 | — | — | US | disclosed |
| US-7772247-B2 | Substituted thieno[3,2-d]pyridines as inhibitors of the VEGF receptor and HGF receptor | METHYLGENE INC. (CA) | 2010-08-10 | — | — | US | disclosed |
| US-7772247-B2 | Substituted thieno[3,2-d]pyridines as inhibitors of the VEGF receptor and HGF receptor | METHYLGENE INC. (CA) | 2010-08-10 | — | — | US | disclosed |
| US-7772247-B2 | Substituted thieno[3,2-d]pyridines as inhibitors of the VEGF receptor and HGF receptor | METHYLGENE INC. (CA) | 2010-08-10 | — | — | US | disclosed |
| WO-2007054831-A2 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE, INC. (CA) | 2007-05-18 | — | — | WO | disclosed |
| EP-1781664-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | Methylgene, Inc. (CA) | 2007-05-09 | — | — | EP | disclosed |
| US-20060287343-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE, INC. | 2006-12-21 | — | — | US | disclosed |
| US-20060074056-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. (CA) | 2006-04-06 | — | — | US | disclosed |
| WO-2006010264-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE, INC. (CA) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074056-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | MET 2/4885KDR 4/4885AURKA 1837/4885 |
| US-20060287343-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | HGF, MET, FLT1 | MET 2/4885KDR 4/4885AURKA 1837/4885 |
| US-20100249145-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signaling | HGF, MET, FLT1 | MET 2/4885KDR 4/4885AURKA 1837/4885 |
| US-20100216766-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signalling | HGF, MET, FLT1 | MET 2/4885KDR 4/4885AURKA 1999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.